Memo Therapeutics AG. (6/11/18). "Press Release: Memo Therapeutics AG Announced that Dr. Karsten Fischer Was Appointed as Chief Executive Officer of the Company Effective June 01, 2018". Basel.

	Organisation	Memo Therapeutics AG
	Organisation 2	BioMedPartners AG
	Group	BioMedPartners (Group)
	Product	MemoMAB™ antibody discovery platform
	Product 2	venture capital
	Person	Fischer, Karsten (Memo Therapeutics 201806– CEO before BioMedPartners + WestLB)
	Person 2	Burckhardt, Peter E. (Basel Inkubator 201603 CEO)

Memo Therapeutics AG announces that Dr. Karsten Fischer was appointed as Chief Executive Officer of the company effective June 01, 2018.

Dr. Fischer will lead the company as its orientation shifts from technological excellence towards pharma partnerships and product development. Founder and former interim CEO, Dr. Christoph Esslinger will focus his efforts as Chief Scientific Officer on the continued advancement of the MemoMAB platform and on the expansion of MEMO’s proprietary antibody discovery programs in immune-oncology and infectious diseases.

Prior to joining MEMO, Dr. Fischer was a partner of BioMedPartners AG and invested in several successful companies in the life science field. Before that, Dr. Fischer has been working for WestLB on equity, M&A, and debt transactions in the healthcare and chemicals sector. Moreover, he has a track record in management consulting with McKinsey and pharmaceutical sales&marketing with Sanofi. He holds a Ph.D. in infection biology (MPI Infection Biology and Colorado State University, with distinction).

“Memo is poised to establish its MemoMAB technology as a world leading platform for antibody discovery and has developed a highly promising pipeline. I am very much looking forward to help the company to manage the next evolutionary step and on bringing its strong value proposition into partnerships and its own pipeline” said Karsten Fischer.

Dr. Peter Burckhardt, Chairman of the Memo Supervisory Board, commented: “As we look to the next phase of growth for Memo, we are very pleased to have been able to recruit Karsten to develop the company to become a major player in the field of therapeutic antibody discovery and development.”

Record changed: 2018-06-14

Picture [iito] – Putting Information into Context 600x102px

More documents for Memo Therapeutics AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Memo Therapeutics AG. (6/11/18). "Press Release: Memo Therapeutics AG Announced that Dr. Karsten Fischer Was Appointed as Chief Executive Officer of the Company Effective June 01, 2018". Basel.

More documents for Memo Therapeutics AG